Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.

about

Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells Systemic therapy for bladder cancer - a medical oncologist's perspective.Tackling non-muscle invasive bladder cancer in the clinic.

P2860

Q28540125-952ADFB1-1E77-4267-AF56-5278639BD678 Q34516731-5F432318-A4AE-4E5C-B418-BD91D9826A6B Q39209020-FA79D054-2710-435D-8055-120F034CE73E

P2860

Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.

Item

http://www.wikidata.org/entity/Q38078886

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Experience with newer intraves ...... uscle-invasive bladder cancer.

@en

type

Item

label

Experience with newer intraves ...... uscle-invasive bladder cancer.

@en

prefLabel

Experience with newer intraves ...... uscle-invasive bladder cancer.

@en

P1476

Experience with newer intraves ...... uscle-invasive bladder cancer.

@en

P2093

LaMont J Barlow

http://www.w3.org/2001/XMLSchema#string

Mitchell C Benson

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy.

Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.

Inactivation of p53 and Pten promotes invasive bladder cancer

A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.

Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.

P2888

s11934-013-0312-2

P304

65-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11934-013-0312-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050373591

http://www.w3.org/2001/XMLSchema#string

P698

23378162

http://www.w3.org/2001/XMLSchema#string

Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.

about

P2860

P2860

Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698